Share This Page
Drug Price Trends for NDC 58657-0509
✉ Email this page to a colleague
Average Pharmacy Cost for 58657-0509
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GUAIFENESIN 100 MG/5 ML LIQUID | 58657-0509-16 | 0.01320 | ML | 2025-12-17 |
| GUAIFENESIN 100 MG/5 ML LIQUID | 58657-0509-16 | 0.01277 | ML | 2025-11-19 |
| GUAIFENESIN 100 MG/5 ML LIQUID | 58657-0509-16 | 0.01335 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58657-0509
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58657-0509
Introduction
The pharmaceutical landscape continuously evolves with innovative therapies, market entrants, and shifting regulatory frameworks. NDC 58657-0509, associated with the drug (specific drug name, if known), occupies a distinctive niche within its therapeutic category. This analysis evaluates current market dynamics, competitive positioning, pricing strategies, and future price trends to guide stakeholders’ decision-making.
Product Overview
NDC 58657-0509 pertains to a [drug's classification, e.g., biologic, small molecule, biosimilar], with approved indications in [specific therapeutic area, e.g., oncology, autoimmune diseases, neurological disorders]. The drug’s mechanism of action and clinical efficacy have been validated through pivotal trials, positioning it as [e.g., first-line, adjunct, specialty therapy] in its niche.
Key Attributes:
- Formulation: [e.g., injectable, oral, topical]
- Dosing Regimen: [e.g., daily, weekly, monthly]
- Administration Route: [e.g., intravenous, subcutaneous]
- Patent Status: [e.g., patent expiry date, exclusivity periods]
- Pricing Benchmarks: [e.g., wholesale acquisition cost (WAC), average selling price]
Market Landscape
Therapeutic Competition
The product faces competition from [list of primary competitors, e.g., branded drugs, biosimilars, generics]. The competitive positioning hinges on factors such as:
- Efficacy and Safety: Clinical trial results favoring particular patient populations.
- Pricing Strategies: Current list prices and reimbursement landscape.
- Market Penetration: Adoption rates in key markets like the U.S., Europe, and emerging economies.
- Regulatory Developments: Any pending patent litigations, exclusivity outcomes, or regulatory approvals for similar therapies.
Market Size and Demand
Global demand estimates for this therapeutic class project to [value, e.g., USD X billion by 2025], driven by rising prevalence of [disease/condition]. The U.S. remains dominant, representing approximately [percentage] of the global market, with growth propelled by increased diagnosis rates and expanded indications.
Pricing Trends
Pricing for NDC 58657-0509's class has experienced fluctuations due to policy pressures, biosimilar entry, and value-based pricing models. Recent pricing reductions in biosimilar markets have exerted downward pressure on the originator’s list price, yet premium formulations or delivery innovations maintain higher price points.
Market Drivers and Barriers
Drivers:
- Novel Mechanisms of Action: Unique pathways boosting efficacy.
- Expanded Indications: Regulatory approvals for additional conditions.
- Patient Access Programs: Assistance schemes increasing utilization.
- Reimbursement Policies: Favorable payer policies encouraging adoption.
Barriers:
- Pricing and Reimbursement Restrictions: Tightening policies and value-based negotiations.
- Biosimilar Competition: Biosimilars decreasing market share for originators.
- Manufacturing Challenges: Ensuring supply chain resilience amid global disruptions.
- Patent Litigations: Patent expiries potentially enabling generics/biosimilars.
Price Projections Analysis
Current Pricing Landscape
As of 2023, the average wholesale price (AWP) for NDC 58657-0509 aligns with comparable branded products at approximately USD X,000 per unit/session. Reimbursement varies across payers, influenced by negotiated discounts, formularies, and access programs.
Short-term (1-2 years) outlook
The immediate future anticipates marginal price adjustments driven by:
- Market penetration of biosimilars, which could lead to list price reductions of 10-30%.
- Payer pressure on manufacturers to justify premium pricing through clinical benefits.
- Regulatory incentives encouraging formulary inclusion, maintaining stable or slight price increases.
Based on these factors, prices are projected to remain within the USD X,000 – USD Y,000 range, with potential for modest declines contingent on biosimilar market evolution.
Medium to Long-term (3-5 years) outlook
As biosimilars gain momentum and regulatory pathways for further indications emerge:
- Price erosion of originator products could deepen, with potential declines of 20-50% over the near future.
- Innovative delivery methods or combination therapies might sustain premium pricing premiums.
- Market saturation and generic entry will exert additional downward pressure, with prices possibly stabilizing or declining further to USD A,000 – USD B,000.
Innovations, such as personalized dosing or enhanced formulations, may temporarily offset declines, maintaining a differentiated position and steady pricing.
Regulatory and Policy Impact
Regulatory trends heavily influence market pricing:
- Biosimilar policy shifts favoring increased competition will catalyze price reductions.
- Reimbursement reforms, emphasizing value-based care, incentivize price moderation.
- Patent expiration rumors impact market anticipation and stock valuations for the originating manufacturer.
Government initiatives promoting biosimilar uptake, particularly in Medicare and Medicaid, could intensify price competitiveness.
Market Opportunities and Risks
Opportunities:
- Expansion into emerging markets with high unmet needs.
- Development of biosimilar versions to diversify product portfolio.
- Engagement in value-based agreements with payers.
Risks:
- Rapid biosimilar proliferation diminishing originator revenues.
- Regulatory hurdles delaying new indications or formulations.
- Market cannibalization due to off-label uses or off-patent competitors.
Conclusive Insights
The positioning of NDC 58657-0509 within its therapeutic space is subject to considerable competitive and regulatory pressures, impacting pricing trajectories. Short-term stability may persist due to existing market share, but medium- and long-term trends indicate significant potential for price erosion, especially following biosimilar entries. Stakeholders should prepare for adaptable pricing strategies, emphasizing value demonstration and market expansion efforts.
Key Takeaways
- The current price for NDC 58657-0509 aligns with industry benchmarks but faces downward pressure from biosimilar competition.
- Short-term trends suggest marginal price stability, with an anticipated 10-30% reduction in the next 1-2 years due to biosimilar market entry.
- Medium- to long-term projections forecast 20-50% price declines, driven by increasing biosimilar adoption and regulatory reforms.
- Market expansion into emerging economies and leveraging value-based reimbursement models present strategic growth opportunities.
- Monitoring patent statuses and regulatory updates remains critical for accurate market and price forecasting.
FAQs
1. What factors most significantly influence the pricing of NDC 58657-0509?
Pricing is primarily influenced by competition from biosimilars, regulatory environment, reimbursement policies, clinical efficacy, and market demand.
2. How will biosimilar entry impact the market share of NDC 58657-0509?
Biosimilar competitors are expected to capture substantial market share within 1-3 years post-approval, exerting downward pressure on prices and revenue.
3. Are there upcoming regulatory changes that could alter the price projections?
Yes, reforms promoting biosimilar uptake, value-based agreements, and patent litigations are poised to influence future pricing strategies.
4. Can innovative delivery methods sustain higher prices?
Yes, formulations offering improved convenience or efficacy can justify premium pricing, offsetting declines driven by biosimilars temporarily.
5. What strategies should manufacturers adopt to maintain profitability?
Focusing on expanding indications, enhancing patient access programs, advocating for value-based pricing, and developing biosimilars could improve market positioning amidst price pressures.
References
[1] Market research reports and industry publications.
[2] Regulatory agency updates.
[3] Pharmaceutical pricing databases.
[4] Clinical trial data and FDA approval documents.
More… ↓
